Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.51 |
| ▸ | IGF1R | P08069 | 4/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.51 |
| ▸ | KIT | P10721 | 4/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.51 |
| ▸ | FLT1 | P17948 | 4/20 | 0.51 |
| ▸ | FLT4 | P35916 | 4/20 | 0.51 |
| ▸ | TEK | Q02763 | 4/20 | 0.51 |
| ▸ | EGFR | P00533 | 3/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.51 |
| ▸ | CAMK2D | Q13557 | 5/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | PRKCB | P05771 | 6/20 | 0.38 |
| ▸ | PRKCA | P17252 | 6/20 | 0.38 |
| ▸ | PRKCH | P24723 | 6/20 | 0.38 |
| ▸ | PRKCE | Q02156 | 6/20 | 0.38 |
| ▸ | PRKCQ | Q04759 | 6/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 6/20 | 0.38 |
| ▸ | CDK4 | P11802 | 4/20 | 0.38 |
| ▸ | CCND1 | P24385 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2349161 | 0.88 | PRKCA (0.51) | KDRIGF1RPDGFRBKITPDGFRA | |
| SCHEMBL2343879 | 0.81 | KDR (0.54) | KDRIGF1RPDGFRBKITPDGFRA | |
| SCHEMBL1395823 | 0.77 | CAMK2D (0.56) | KDRIGF1RPDGFRBKITPDGFRA | |
| SCHEMBL2340281 | 0.75 | GSK3B (0.43) | PRKCBPRKCAPRKCQGSK3B | |
| SCHEMBL7826604 | 0.74 | KDR (0.68) | KDRIGF1RPDGFRBKITPDGFRA | |
| SCHEMBL2362243 | 0.73 | OPA1 (0.48) | SLC6A4CDK4CCND1CDK2CCNE2 | |
| SCHEMBL13241003 | 0.73 | OPA1 (0.48) | SLC6A4CDK4CCND1CDK2CCNE2 | |
| SCHEMBL2344815 | 0.70 | GSK3B (0.44) | PRKCAGSK3B | |
| SCHEMBL6327465 | 0.70 | CDK4 (0.56) | CAMK2DPRKCBPRKCAPRKCHPRKCE | |
| SCHEMBL6030138 | 0.69 | CAMK2D (0.61) | KDRIGF1RPDGFRBKITPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513292-B2 | Compositions and methods for the treatment of cancer | ARQULE, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513292-B2 | Compositions and methods for the treatment of cancer | ARQULE, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513292-B2 | Compositions and methods for the treatment of cancer | ARQULE, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2392574-A1 | Indolyl pyrrolidines for the treatment of cancer | ArQule, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2173748-B1 | INDOLYL PYRROLIDINES FOR THE TREATMENT OF CANCER | ARQULE INC (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20100183603-A1 | Compositions and Methods for the Treatment of Cancer | ARQULE, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100183603-A1 | Compositions and Methods for the Treatment of Cancer | ARQULE, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100183603-A1 | Compositions and Methods for the Treatment of Cancer | ARQULE, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| EP-2173748-A2 | INDOLYL PYRROLIDINES FOR THE TREATMENT OF CANCER | ArQule, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009002807-A2 | INDOLYL PYRROLIDINES FOR THE TREATMENT OF CANCER | ARQULE, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183603-A1 | Compositions and Methods for the Treatment of Cancer | MKI67, POLI, DHPS | KDR 3409/4885IGF1R 1723/4885PDGFRB 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.